A Study of CS1001 in Combination With Regorafenib in Patients With Advanced or Refractory Solid Tumors
Status:
Recruiting
Trial end date:
2023-07-30
Target enrollment:
Participant gender:
Summary
This is a multicenter, open-label study of CS1001 in combination with regorafenib in
participants with advanced or refractory cancers. There will be a dose escalation portion in
"allcomers"to find a suitable dose of regorafenib for combination use with CS1001. This study
will also enroll participants with specific tumor types in the phase II part of the study to
assess the efficacy, pharmacokinetics and safety of the combined regimen (RP2D of regorafenib
+ CS 1001)